[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Servier Russia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":61},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100642507","evaluation-of-the-effectiveness-of-micronized-purified-flavonoid-fraction-mpff-in-patients-with-haemorrhoids-undergoing-minimally-invasive-surgical-interventions-100642507",false,"NCT07647172","Evaluation of the Effectiveness of Micronized Purified Flavonoid Fraction (MPFF) in Patients With Haemorrhoids Undergoing Minimally Invasive Surgical Interventions","Evaluation of the Effectiveness of Micronized Purified Flavonoid Fraction (MPFF) as Part of the Conservative Therapy and Impact on Quality of Life and Satisfaction With Treatment in the Real-life Clinical Practice in Patients With Haemorrhoids Undergoing Minimally Invasive Surgical Interventions","DEMAND HD","Inclusion Criteria:\n\n* Males and females aged over 18 years.\n* Informing the patient in writing about the inclusion in the study and his\u002Fher consent to participate in it.\n* Absence of conditions requiring urgent medical care.\n* The patient was diagnosed with chronic hemorrhoids of grade 2 or 3 according to Goligher classification.\n* The patient is scheduled to undergo one of the listed types of minimally invasive surgical treatment within 7 ± 2 days from the inclusion in the study (V0):\n* laser vaporization (laser submucosal destruction or ablation);\n* transanal dearterialization (hemorrhoidal artery ligation);\n* transanal dearterialization + laser vaporization (laser submucosal destruction or ablation);\n* transanal dearterialization + sclerotherapy.\n* No venoactive drug treatment within 4 weeks prior to inclusion in the study.\n* The patient has been prescribed with MPFF at the inclusion visit, or it is planned to prescribe MPFF-containing drug in the postoperative period (for cluster 1 sites), or the patient has not been prescribed with any systemic venoactive drug, and it is not planned to prescribe it the postoperative period (for cluster 2 sites).\\*\n\nExclusion Criteria:\n\n* Pregnancy or breast-feeding, or planning for pregnancy during the study or at least in two months after its completion.\n* Confirmed or suspected malignancy.\n* Severe somatic disorder (of heart or blood vessels, lungs, kidneys, pancreas, or liver), accompanied by the organ function decompensation.\n* Mental disorder.\n* Contraindications for examination.\n* Predicted unwillingness of the patient to follow the protocol of treatment and supervision, poor adherence to treatment.\n* Patient's participation in any interventional\u002Fobservational study at the present time.\n* Patients who received venoactive drugs in the 4 weeks prior to Visit 0 (inclusion visit).","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","Evaluation of the effectiveness of micronized purified flavonoid fraction (MPFF) as part of the conservative therapy and impact on quality of life and satisfaction with treatment in the real-life clinical practice in patients with haemorrhoids undergoing minimally invasive surgical interventions",[25],"Haemorrhoids","NOT_YET_RECRUITING","2026-06-09",{"date":29,"type":30},"2026-06-15","ACTUAL",{"date":32,"type":21},"2026-07-01",{"date":34,"type":21},"2027-04-01",{"name":36,"class":37},"Servier Russia","INDUSTRY",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},"100626250","polus-description-of-the-effectiveness-and-tolerability-of-luseogliflozin-in-patients-with-type-2-diabetes-100626250","NCT07433192","POLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes.","Multicenter Observational Study POLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes in Real-world Clinical Practice.","POLUS","Inclusion Criteria:\n\n* Men and women aged 18 years and older.\n* Patients with type 2 diabetes.\n* Written informed consent of the patient to participate in the study.\n* No conditions that require emergency medical aid.\n* Treatment with luseogliflozin started 7 to 30 days prior to the inclusion visit as part of routine clinical practice and in accordance with the SmPC approved in the Russian Federation.\n* Presence of data on the parameters of interest (HbA1c, eGFR, BP, body weight), dated no later than 15 days from the date the treatment with luseogliflozin was started\n\nExclusion Criteria:\n\n* Patients cannot be included in this study if they meet at least one of the following exclusion criteria:\n* Known hypersensitivity to luseogliflozin or other components of Lusefi®.\n* Type 1 diabetes.\n* Decompensated type 2 diabetes.\n* Pregnancy, breastfeeding, or planned pregnancy during the study and at least two months after the study.\n* Severe renal failure (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2), end-stage chronic kidney disease (CKD) or dialysis, as the treatment is predicted to be ineffective in this population of patients.\n* Diabetic ketoacidosis, diabetic coma or precoma.\n* Severe infections, pre- and postoperative period, or severe injury.\n* Any suspected or confirmed malignant neoplasm, including a history of malignancy within ≤5 years prior to screening, excluding successfully treated basal cell carcinoma and squamous cell carcinoma of the skin or in situ cervical cancer.\n* Urinary tract infection (confirmed or suspected).\n* Other concomitant disorders considered by the investigator to affect the natural progression of the disease and significantly impact the treatment results.\n* Predictable unwillingness of the patient to adhere to the treatment regimen and\u002For cooperate with the investigator.\n* Participation of the patient in another clinical study within 3 months (6 months for biological medicinal products) prior to the inclusion visit or during this study.",{"count":47,"type":21},300,"In this non-interventional study, the effectiveness and tolerability of Lusefi® in adult patients with type 2 diabetes will be evaluated.",[50],"Type 2 Diabetes Mellitus","RECRUITING","2026-04-29",{"date":54,"type":30},"2026-04-30",{"date":56,"type":30},"2026-03-02",{"date":58,"type":21},"2027-09-01",{"name":36,"class":37},1,""]